<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807335</url>
  </required_header>
  <id_info>
    <org_study_id>PDC 01-0204</org_study_id>
    <nct_id>NCT04807335</nct_id>
  </id_info>
  <brief_title>Study of CT001 in Healthy Volunteers</brief_title>
  <official_title>Bioavailability Study of Intranasal CT001 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cessatech A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dantrials Aps</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Smerud Medical Research International AS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cessatech A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1, three arms, cross over comparison study to evaluate bioavailability,&#xD;
      pharmacokinetics and safety of intra nasal CT001 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single site phase 1 study including a randomised, open label, three periods, single dose,&#xD;
      cross over design in 12 healthy male volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Actual">June 2, 2021</completion_date>
  <primary_completion_date type="Actual">June 2, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>concentration of CT001 in the blood</measure>
    <time_frame>baseline, 3, 5, 10, 15, 30, 60, 90, 180, 240 minutes and 6, 9, 24, 32, 48 hours after dose</time_frame>
    <description>maximum concentration over time C(max),</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total amount of CT001 in the blood over time</measure>
    <time_frame>baseline, 3, 5, 10, 15, 30, 60, 90, 180, 240 minutes and 6, 9, 24, 32, 48 hours after dose</time_frame>
    <description>Area under the curve calculated from t=0 to t= 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>distribution and elimination of CT001</measure>
    <time_frame>baseline, 3, 5, 10, 15, 30, 60, 90, 180, 240 minutes and 6, 9, 24, 32, 48 hours after dose</time_frame>
    <description>Volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of study participants with adverse events</measure>
    <time_frame>from baseline to 48 hours post dose</time_frame>
    <description>Number andproportion of adverse events,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>elimination of CT001</measure>
    <time_frame>from baseline to 48 hours</time_frame>
    <description>Half time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital signs</measure>
    <time_frame>from baseline to 48 hours</time_frame>
    <description>heart rate, blood pressure, respiratory rate and blood oxygen level</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>Investigational medicinal product CT001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal dosage of CT001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketamine 10mg iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sufentanil 10mcg iv</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT001</intervention_name>
    <description>nasal spray</description>
    <arm_group_label>Investigational medicinal product CT001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>iv single dose</description>
    <arm_group_label>Comparator 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sufentanil</intervention_name>
    <description>iv single dose</description>
    <arm_group_label>Comparator 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age from 18 up to 55 years&#xD;
&#xD;
          -  Non-smokers&#xD;
&#xD;
          -  Body mass index (BMI) from 18.5 kg/m2 up to 30 kg/m2 v) Categorized as American&#xD;
             Society of Anesthesiologists (ASA)&#xD;
&#xD;
          -  Physical Status Class 1 or 2&#xD;
&#xD;
          -  Clinically normal medical history, physical findings, vital signs, ECG and laboratory&#xD;
             values.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mental illness&#xD;
&#xD;
          -  Opioid Risk Tool score of &gt;3&#xD;
&#xD;
          -  Pain Catastrophizing Scale score, total points &gt;30&#xD;
&#xD;
          -  Hospital Anxiety and Depression Scale (HADS), points ≥11 for anxiety or ≥11 points for&#xD;
             depression&#xD;
&#xD;
          -  Daily intake of analgesics&#xD;
&#xD;
          -  History of alcohol or drug abuse or use of illicit drugs.&#xD;
&#xD;
          -  Use of prescription drugs within 14 days or over-the-counter drugs 24 hours&#xD;
             (intranasal medication 48 hours) prior to the first dose of study medication.&#xD;
&#xD;
          -  Participant showing abnormal nasal cavity/airway&#xD;
&#xD;
          -  History or presence of allergy to the study drug or drugs of this class, or a history&#xD;
             of drug or other allergy.&#xD;
&#xD;
          -  Positive tests for HIV, hepatitis B and hepatitis C&#xD;
&#xD;
          -  Positive COVID-19 test or clinical symptoms of COVID-19&#xD;
&#xD;
          -  Is currently participating in or has participated in an interventional clinical trial&#xD;
             with an investigational compound or device within 30 days of signing the informed&#xD;
             consent for this trial&#xD;
&#xD;
          -  Blood donation within 4 weeks prior to the first dosing visit&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mads Werner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dantrials</name>
      <address>
        <city>Copenhagen</city>
        <state>DK</state>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://cessatech.com</url>
    <description>sponsor's homepage</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

